GlucoGuard Receives Scope of Work (SOW) Proposal from Arete Bioscience for FDA Recommended Sleep Study
MWN-AI** Summary
American Diversified Holdings Corporation (OTCID: ADHC) has announced that its product GlucoGuard has received a crucial Scope of Work (SOW) proposal from Arete Bioscience. This follows a recent meeting with the FDA, where officials indicated that GlucoGuard's Break Through Device (BTD) application met the necessary criteria for approval but raised questions regarding the risk of aspiration for patients during a sleep study involving glucose gel administration.
The SOW entails a two-prong approach, featuring a physician-monitored sleep study with 10 patients. The goal of the study is to observe the risk of glucose aspiration and to measure the effect on blood sugar levels before and after the administration of the glucose. Previous research conducted by GlucoGuard’s Medical Advisory Board, spearheaded by Dr. Stephen Weber, MD, demonstrated positive outcomes related to both concerns in neonatal patients, establishing a nominal risk of aspiration and effectiveness in elevating blood glucose levels.
Dr. Sur and the Arete Bioscience team will lead the upcoming study, backed by reputable data from previous studies in New Zealand and Ireland. ADHC expressed optimism that the study will address FDA concerns effectively, deemed essential for the potential rollout of GlucoGuard.
The sleep study is expected to commence shortly, contingent upon standard scheduling processes. Additionally, ADHC is actively seeking engagement with investment banking entities to secure financial support for the GlucoGuard project, with further updates anticipated soon. The company remains committed to transparency in its developments and encourages interested parties to stay informed through their official communication channels and social media.
MWN-AI** Analysis
American Diversified Holdings Corporation's (ADHC) recent announcement concerning GlucoGuard's receipt of a Scope of Work (SOW) proposal from Arete Bioscience marks a significant step forward in addressing FDA concerns regarding their Breakthrough Device (BTD) application. The planned physician-monitored sleep study will focus on the risks associated with glucose aspiration in patients while also aiming to validate the product's efficacy in increasing blood sugar levels safely.
Investors should look favorably upon the proactive approach taken by GlucoGuard and its Medical Advisory Board led by Dr. Stephen Weber. The positive research outcomes in neonatal patients, combined with the collaboration with Arete Bioscience, indicate a commitment to meeting FDA requirements comprehensively. The comprehensive nature of the SOW suggests a well-structured plan to carry out the sleep study, which should provide substantial data necessary for furthering the application's success.
However, it’s essential for potential investors to be cognizant of the inherent risks still present. Although previous studies have shown nominal risks associated with aspiration and successful blood glucose alteration, any unfavorable findings from the forthcoming study could significantly impact stock value and investor confidence. The dynamic nature of FDA approvals and the overall clinical landscape can also bring unforeseen challenges.
Given that ADHC is currently engaging with investment banking partners to support GlucoGuard, investors should monitor forthcoming updates closely; successful fundraising could bolster the project's momentum.
In conclusion, while there exists positive momentum for GlucoGuard, potential investors should approach with caution. Carefully weigh the projected growth against the possible risks outlined in regulatory developments and clinical outcomes as the sleep study progresses. Keeping informed on FDA communications and GlucoGuard’s engagement with the investment community will be crucial for strategic investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
2 Prong Proposal Includes a 10 Patient, Physician Monitored Sleep Study to Observe Glucose Aspiration Risk and Record Effect of Blood Sugar Level Before and After Administration of Glucose
Del Mar, California--(Newsfile Corp. - October 14, 2025) - American Diversified Holdings Corporation (OTCID: ADHC) announces today the GlucoGuard received a formal SCOPE OF WORK (SOW) from Arete Bioscience in response to the company's recent meeting with FDA officials.
The FDA had indicated during this meeting that all criterion were met to approve the Break Through Device (BTD) Application but concerns about a sleeping patient potential for aspirating on the proposed quantity of glucose gel into the patient's buccal cavity. Additionally, the FDA requested a recording of the patient's glucose level before and after the administration of the glucose to determine if the patient would bee end points required to increase the patient's blood glucose from a Hypoglycemic state into the normal range.
Glucoguard's Medical Advisory Board, led by Dr. Stephen Weber, MD submitted research studies that established positive results on both points in neo-natal patients. Based upon this research coming from highly reputably studies in New Zealand and Ireland the Medical Advisory Board is confident the sleep study will achieve favorable results.
GlucoGuard's previous BTD application included in depth research involving both issues with neo natal patients, adequately establishing both a nominal risk of aspiration and a successful increase in the blood glucose level in newborn babies. Based upon this research it is the opinion of the GlucoGuard team that these two issues can be successfully addressed in the study that will be conducted by Dr. Sur and the Arete Bioscience team.
"After meeting with several sleep study labs and conferring with other experts in the field, Arete has been able to submit a comprehensive SOW, that is projected to meet all of the FDA's concerns," commented ADHC.
It is anticipated the sleep study will be initiated in the near term pending normal scheduling issues. Additionally, ADHC is continuing to engage investment banking concerns to support the Glucoguard project. More news on this front should be forthcoming soon.
Contact:Phone: 817-525-0057
www.GlucoGuardSleep.com
www.UniversalWellnessAI.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
Twitter: @ADHCManagement
(This Twitter page is the only official Twitter page for ADHC.)
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270318
FAQ**
How does Amer Divrsfd Hldgs Corp ADHC plan to address the FDA's concerns regarding the risk of aspiration during the sleep study for the GlucoGuard device?
What specific metrics will be used to evaluate the success of the glucose level increase in patients following the administration of glucose gel as part of the study?
Can you elaborate on the previous research studies done in neonatal patients that support the safety and efficacy of GlucoGuard, and how they relate to the current sleep study?
What are the anticipated next steps for Amer Divrsfd Hldgs Corp ADHC in engaging with investment banking concerns to support the GlucoGuard project following the completion of the sleep study?
**MWN-AI FAQ is based on asking OpenAI questions about Amer Divrsfd Hldgs Corp (OTC: ADHC).
NASDAQ: ADHC
ADHC Trading
0.0% G/L:
$0.0009 Last:
199,700 Volume:
$0.0009 Open:
